Verastem Inc.

1.67-0.0100-0.60%Vol 3.02M1Y Perf 21.59%
Jul 2nd, 2020 16:00 DELAYED
BID1.68 ASK1.69
Open1.69 Previous Close1.68
Pre-Market- After-Market1.69
 -1.68 -100.00%  0.02 1.20%
Target Price
4.00 
Analyst Rating
Moderate Buy 1.67
Potential %
139.52 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap271.43M 
Earnings Rating
Neutral
Price Range Ratio 52W %
21.88 
Earnings Date
6th Aug 2020

Today's Price Range

1.651.70

52W Range

0.83004.67

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-4.02%
1 Month
-8.74%
3 Months
-32.11%
6 Months
28.46%
1 Year
21.59%
3 Years
-23.74%
5 Years
-76.35%
10 Years
-

TickerPriceChg.Chg.%
VSTM1.67-0.0100-0.60
AAPL368.514.40001.21
GOOG1 464.7026.66001.85
MSFT206.261.56000.76
XOM44.080.37000.85
WFC25.340.25001.00
JNJ140.970.59000.42
FB233.42-4.1300-1.74
GE6.820.08001.19
JPM92.66-0.6000-0.64
Earnings HistoryEstimateReportedSurprise %
Q01 2020-0.19-0.35-84.21
Q04 2019--0.51-
Q03 2019-0.42-0.3516.67
Q02 2019-0.49-0.52-6.12
Q01 2019-0.46-0.51-10.87
Q04 2018-0.54-0.3731.48
Q03 2018-0.43-0.2932.56
Q02 2018-0.35-0.3014.29
Earnings Per EndEstimateRevision %Trend
6/2020 QR-0.156.25Positive
9/2020 QR-0.137.14Positive
12/2020 FY-0.76-31.03Negative
12/2021 FY-0.5634.88Positive
Next Report Date6th Aug 2020
Estimated EPS Next Report-0.15
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume3.02M
Shares Outstanding162.53M
Trades Count6.59K
Dollar Volume5.00M
Avg. Volume5.33M
Avg. Weekly Volume10.63M
Avg. Monthly Volume7.35M
Avg. Quarterly Volume7.97M

Verastem Inc. (NASDAQ: VSTM) stock closed at 1.67 per share at the end of the most recent trading day (a -0.6% change compared to the prior day closing price) with a volume of 3.11M shares and market capitalization of 271.43M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 169 people. Verastem Inc. CEO is Brian M. Stuglik.

The one-year performance of Verastem Inc. stock is 21.59%, while year-to-date (YTD) performance is 24.63%. VSTM stock has a five-year performance of -76.35%. Its 52-week range is between 0.83 and 4.6699, which gives VSTM stock a 52-week price range ratio of 21.88%

Verastem Inc. currently has a PE ratio of -, a price-to-book (PB) ratio of 2.30, a price-to-sale (PS) ratio of 13.26, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -66.04%, a ROC of -63.55% and a ROE of -141.03%. The company’s profit margin is -%, its EBITDA margin is -578.80%, and its revenue ttm is $20.84 Million , which makes it $0.13 revenue per share.

Of the last four earnings reports from Verastem Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.15 for the next earnings report. Verastem Inc.’s next earnings report date is 06th Aug 2020.

The consensus rating of Wall Street analysts for Verastem Inc. is Moderate Buy (1.67), with a target price of $4, which is +139.52% compared to the current price. The earnings rating for Verastem Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Verastem Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Verastem Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 16.02, ATR14 : 0.13, CCI20 : -114.67, Chaikin Money Flow : -0.10, MACD : -0.06, Money Flow Index : 39.35, ROC : -4.02, RSI : 39.49, STOCH (14,3) : 15.49, STOCH RSI : 0.00, UO : 47.97, Williams %R : -84.51), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Verastem Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (66.67 %)
2 (66.67 %)
1 (50.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (33.33 %)
1 (33.33 %)
1 (50.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.67
Moderate Buy
1.67
Moderate Buy
2.00

Verastem Inc.

Verastem Oncology is a part of the healthcare sector. It is a commercial-stage company focused on discovering and developing drugs to aid patients suffering from cancer. The company's first commercial product, COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma after at least two prior systemic therapies. The Company's product pipeline candidate, defactinib, is a focal adhesion kinase inhibitor in development for the treatment of cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.

CEO: Brian M. Stuglik

Teplephone: +1 781 292-4200

Address: 117 Kendrick Street, Needham 02494, MA, USA

Number of employees: 169

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

63%38%

Bearish Bullish

66%34%

Bearish Bullish

56%44%

News

Stocktwits